ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.04B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.45M
Average 1.66M
Returns on capital
ACADIA Pharmaceuticals Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
31.9%
avg -35.2%
ROIC
8.1%
avg -37.0%
ROA
25.0%
avg -30.4%
Analysis
ROE is currently the strongest return metric at 31.9% versus its period average of -35.2%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Catherine E. Owen Adams | Chief Executive Officer & Director | USD 1.78M | 56 | — | — |
Elizabeth Thompson | Executive Vice President and Head of Research & Development | USD 1.04M | 50 | — | — |
Mark C. Schneyer | Executive Vice President & Chief Financial Officer | USD 877.94K | 52 | 71.32K | 0.04% |
Jennifer J. Rhodes | Executive Vice President, Chief Legal Officer & Secretary | USD 857.88K | 56 | 11.28K | <0.01% |
Thomas Andrew Garner | Executive Vice President & Chief Commercial Officer | USD 857.02K | 50 | — | — |
Albert S. Kildani | Senior Vice President of Investor Relations & Corporate Communications | — | — | — | — |
Carl Segerstrom | Chief People Officer | — | — | — | — |
James K. Kihara | Senior Vice President of Finance | — | 45 | — | — |
Scott Cenci | Senior Vice President, Chief Information & Data Officer | — | — | — | — |
Allyson McMillan Youngblood | Senior Vice President of Rare Disease Franchise | — | — | — | — |
Konstantina Katcheves | Senior Vice President, Chief Business & Strategy Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
22
$2.46M
Net Transaction Value
−$2.46M
Net selling
Most Active
Schneyer Mark C.
9 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 30, 26Oct 30, 2026 | Schneyer Mark C. Direct | Sell | $69.3K$69,342.48 |
| Aug 6, 26Aug 6, 2026 | Schneyer Mark C. Direct | Sell | $145K$145,000.00 |
| Aug 6, 26Aug 6, 2026 | Schneyer Mark C. Direct | Sell | $272.6K$272,604.05 |
| Aug 5, 26Aug 5, 2026 | Schneyer Mark C. Direct | Sell | $169.6K$169,637.96 |
| Jul 30, 26Jul 30, 2026 | Thompson Elizabeth H.Z. Direct | Sell | $431.4K$431,354.04 |
| Jul 30, 26Jul 30, 2026 | Thompson Elizabeth H.Z. Direct | Sell | $1.3K$1,308.50 |
| Jun 26, 26Jun 26, 2026 | Kihara James Direct | Sell | $297.9K$297,912.22 |
| May 26, 26May 26, 2026 | Kihara James Direct | Sell | $114.4K$114,393.18 |
| May 4, 26May 4, 2026 | Schneyer Mark C. Direct | Sell | $76.4K$76,395.74 |
| May 4, 26May 4, 2026 | Kihara James Direct | Sell | $29K$29,024.28 |
1–10 of 22
Summary
Insiders reported 0 buys worth $0.00 and 22 sells worth $2.46M over the last 12 months. That adds up to net selling of $2.46M. Schneyer Mark C. was the most active insider with 9 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +1.3% (5yr)5 analysts |
| Revenue | N/A | N/A | +27.5% | +11.2% (5yr)12 analysts |
| Net Income | N/A | N/A | N/A | +1.3% (5yr)12 analysts |
| EBIT | N/A | N/A | N/A | +38.2% (5yr)12 analysts |
Analysis
Recent growth has been strongest in Revenue at +27.5% over three years. Forward estimates point to EBIT at +38.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does ACADIA Pharmaceuticals Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Market cap
$9.17B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Market cap
$7.45B
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Market cap
$1.39B
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Market cap
$1.25B
Alto Neuroscience, Inc.
NYSE:ANRO
Market cap
$1.18B
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
Market cap
$348.58M
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Market cap
$308.98M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Market cap
$241.27M
Anavex Life Sciences Corp.
NASDAQ:AVXL
Market cap
$86.53M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Market cap
$80.59M
Questions
Management questions
Common questions about ACAD's management, answered from reported figures.
Who manages ACAD?
ACADIA Pharmaceuticals Inc. (ACAD) lists 11 active executives. The top listed executive is Elizabeth Thompson, Executive Vice President and Head of Research & Development.
Are ACAD insiders buying or selling?
Recent insider activity shows net buying of $35.44M.
Continue the stock analysis
Jump to another research area for this company.